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Abstract
Background: We investigated the prevalence of wild-type virus (no major drug resistance) and drug resistance mutations at
second-line antiretroviral treatment (ART) failure in a large HIV treatment program in South Africa.
Methodology/ Principal Findings: HIV-infected patients $15 years of age who had failed protease inhibitor (PI)-based
second-line ART (2 consecutive HIV RNA tests .1000 copies/ml on lopinavir/ritonavir, didanosine, and zidovudine) were
identified retrospectively. Patients with virologic failure were continued on second-line ART. Genotypic testing for drug
resistance was performed on frozen plasma samples obtained closest to and after the date of laboratory confirmed second-
line ART failure. Of 322 HIV-infected patients on second-line ART, 43 were adults with confirmed virologic failure, and 33 had
available plasma for viral sequencing. HIV-1 RNA subtype C predominated (n=32, 97%). Mean duration on ART (SD) prior to
initiation of second-line ART was 23 (17) months, and time from second-line ART initiation to failure was 10 (9) months.
Plasma samples were obtained 7(9) months from confirmed failure. At second-line failure, 22 patients (67%) had wild-type
virus. There was no major resistance to PIs found. Eleven of 33 patients had a second plasma sample taken 8 (5.5) months
after the first. Median HIV-1 RNA and the genotypic resistance profile were unchanged.
Conclusions/ Significance: Most patients who failed second-line ART had wild-type virus. We did not observe evolution of
resistance despite continuation of PI-based ART after failure. Interventions that successfully improve adherence could allow
patients to continue to benefit from second-line ART therapy even after initial failure.
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Introduction
South Africa has the largest government-sponsored antiretrovi-
ral treatment (ART) program in the world [1]. Given the scarcity
of salvage ART regimens in South Africa and other resource-
limited settings and the high cost of second-line ART [2], rational
use of second-line ART is critical.
International guidelines endorse boosted protease inhibitor (PI)-
based combination ART as an efficacious strategy after failure of
NNTRI-based first line ART [3]. Most adults are PI-naive at
second-line ART initiation, PI resistance at failure of first-line
NNRTI-based ART is uncommon [4], and PI-based second-line
ART is highly potent [5]. Nevertheless, up to 40% of HIV-1
infected adults in South Africa develop confirmed virologic failure
on second-line ART [6,7,8,9].
In resource-limited settings such as South Africa, many
unanswered questions remain about the contribution of drug
resistance to second-line ART failure. They include uncertainties
about the susceptibility of HIV-1 subtype C, which accounts for
nearly half of global infections and the majority in South Africa
[4,10,11]; effectiveness of ART delivery in public health clinics;
and medication non-adherence.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32144Here, we investigated the extent to which drug resistance
mutations contribute to second-line ART failure in a large
community-based ART program in South Africa.
Methods
Ethics Statement
All study participants provided written informed consent. For
participants age #18 years, an accompanying parent or guardian
also provided written consent. Study procedures were approved by
the University of Cape Town (Cape Town, South Africa) and the
Partners HealthCare Human Research Committee (Boston,
Massachusetts, USA).
Study setting and population
The Gugulethu Clinic is an HIV referral center for a peri-urban
township of Cape Town, South Africa. The clinic provides HIV-
related care for more than 6,000 patients and serves an
impoverished population of more than 300,000 individuals where
the ante-natal HIV seroprevalence was 29% in 2006 [9,12,13].
Clinic demographic and clinical characteristics are consistent with
other large ART roll-out programs in South Africa [10,14].
Clinical data are prospectively maintained in an electronic
database at the Desmond Tutu HIV Center. First-line ART
consists of stavudine in the majority of cases, or zidovudine, with
lamivudine and either efavirenz or nevirapine. Second-line ART
includes zidovudine, didanosine, and lopinavir/ritonavir as per
national protocol [15]. Consistent with national ART guidelines,
patients were eligible to switch to second-line ART if they have
persistent observed HIV viremia (HIV RNA.1000 copies/ml) at
2 consecutive occasions 3 months apart, despite an adherence
intervention [15]. Patients with virologic failure are generally
continued on second-line ART.
Study Design
Data from HIV-infected patients $15 years of age who had
failed second-line therapy (2 consecutive HIV-1 RNA tests .1000
copies/ml) by October 1, 2009, were analyzed retrospectively
using a cross sectional design. A single local laboratory performed
HIV-1 RNA assays by branch DNA hybridization techniques
(HIV-1 RNA 3.0 assayH; Bayer Healthcare, Leverkusen, Ger-
many) and CD4-count by flow cytometry (FACS Count
TM,
Becton, Dickinson and Company, Franklin Lakes, NJ, USA).
Genotypic testing for drug resistance was performed on frozen
plasma samples obtained closest to, and on or after the date of
laboratory confirmed second-line ART failure. We used Interna-
tional AIDS Society-USA criteria to define drug resistance
mutations [16]. Some patients who failed second-line ART had
genotypic drug resistance results available from first-line ART
failure [4].
Viral sequencing from plasma
Viral RNA was extracted (QIAamp viral RNA minikit,
QIAGEN Inc) from 140 ml of each plasma sample and HIV-1
protease (PR codons 1–99, HXB2 nucleotides 2254–2549) and
reverse transcriptase (RT codons 1–343, HXB2 nucleotides 2550–
3577) were amplified by a 1-step reverse transcription–polymerase
chain reaction (PCR), followed by a nested-PCR using gene-
specific primers, as described [17].
Population (‘‘bulk’’) sequencing was performed on resulting
amplicons with the Taq Dye Deoxy Terminator Kit (Applied
Biosystems, Inc.) and resolved on an ABI 3730 automated DNA
sequencer. Sequence processing was done using the Sequencher
program (Genecodes). Sequences were aligned to the HIV-1
subtype B reference strain HXB2 (GenBank accession
no. K03455).
Each sample was amplified in duplicate. A phylogenetic tree,
using the PhyML program and including all the sequences
generated as well as HXB2 and NL4-3 corresponding sequences,
was used to confirm specimen identity and the absence of cross-
contamination as an adjunct to the PCR negative control.
Statistical Analysis
Mean values were reported with standard deviations (SD).
Demographic and laboratory characteristics were examined for
association with drug-resistant virus at second-line ART failure.
We used Fisher’s exact test to compare the association of
categorical variables, age dichotomized at the mean (#35 or
.35 years), and HIV-1 RNA (#10,000 copies/ml and .10,000
copies/ml) with the outcome. Statistical tests were two-sided with a
significance level of 0.05. All statistical analyses were performed
using SAS 9.1 software (Cary, North Carolina).
Results
Of 322 HIV-infected patients receiving second-line ART, 43
were adults ($15 years) with confirmed virologic failure (Figure 1).
Of these, 33 had plasma available for viral sequencing. No
differences in age (p=0.19), sex (p=0.66), or viral load (p=0.83)
at second-line ART failure were found when comparing the 10
adults without plasma available for sequencing to the analyzed
cohort. Of the 33 adults, mean (SD) age was 34 (8) years; 28
(85%) were female. HIV-1 RNA subtype C predominated
(n=32, 97%). Thirty-two of 33 individuals had available first-
line treatment history. The majority (n=30; 94%) received a
stavudine-lamivudine based regimen; the remainder received
zidovudine-lamivudine. Similarly, most patients received efavir-
enz as the NNRTI component (n=24; 75%), and the rest
received nevirapine. Mean (SD) duration on ART prior to
initiation of second-line treatment was 23 (17) months. The
median time between confirmatory HIV viral loads on second-
line ART was 7 months. Mean time from second-line ART
initiation to failure was 10 (9) months. Plasma samples available
for analysis were obtained a mean of 7 (9) months from confirmed
second-line failure.
At second-line ART initiation, median CD4 count was 210/ml
[IQR 108–310/ml] and median HIV-1 RNA was 4.1 log10 copies/
ml [IQR 3.5–4.7 log10 copies/ml], which increased to a median
HIV-1 RNA of 4.6 log10 copies/ml [IQR 4.1–5.1 log10 copies/ml]
at second-line failure.
At the first sample collection at second-line failure, virus from 22
patients (67%) was wild-type or lacked major drug resistance
mutations (Table 1). Among samples with resistance mutations,
NRTI resistance mutations were rare. Samples from 11 patients
(33%) had major NNRTI resistance; of these, 9 patients had virus
with only major NNRTI resistance and 2 patients had virus with
both NRTI and NNRTI resistance. The most common NNRTI
mutation was K103N (n=5, 15%) found alone in 4 patients and
with Y181C in another patient. Both Y181C (n=3, 9%) and
G190A (n=3, 9%) were present with other resistance mutations.
P225H (n=1, 3%) occurred without other NNRTI resistance
mutations. Resistance mutations that may reduce susceptibility to
etravirine were assessed and were infrequent (Table 1).
Mutations classified as ‘‘minor’’ PI resistance mutations by the
IAS-USA were detected in 30 of 33 (91%) individuals; no major PI
resistance mutations were found. The most frequent minor PI
resistance mutations included K20R (n=9, 27%); M36I (n=30,
91%), L63P (n=14, 42%), H69K (n=32, 97%), and I93L (n=31,
Resistance at 2nd-Line ART Failure in South Africa
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6%) D60E (n=5, 15%), and I62V (n=3, 9%).
Ten individuals had HIV-1 genotypes from the time of first-
line ART failure available. The same minor PI resistance
mutations present at second-line ART failure were also present
at first-line ART failure, prior to PI exposure. Virus from 8
individuals had M184V at first-line ART failure; in 7 individuals
this mutation was undetectable at second-line failure. All samples
in which the M184V mutation was detected at first-line failure
also carried major NNRTI resistance mutations. Of the 9
individuals with virus containing major NNRTI resistance
mutations at first-line failure, 6 retained virus with detectable
major NNRTI resistance mutations at second-line failure.
Samples from 2 individuals had thymidine analog mutations
(TAMs) at first-line ART failure, which were not detected at
second-line ART failure.
Eleven of 33 patients had a second sample for resistance testing
taken 8 (5.5) months after the first sample at second-line failure.
Median HIV-1 RNA was unchanged from the first sample at 4.5
log10 copies/ml [IQR 3.5–5.0 log10 copies/ml]. The genotypic
resistance profile was also unchanged. Mean genotypic suscepti-
bility score was 2.9 (60.4) at second-line failure; this was
unchanged for those with a repeat sample.
In patients aged 15–35 years, 29% had drug-resistant virus,
compared with 42% of those aged .35 years, although this
difference did not reach statistical significance. Thirty-one percent
of individuals failing treatment with HIV RNA.10,000 copies/ml
had drug-resistant virus, compared with 43% of individuals with
HIV RNA#10,000 copies/ml (p=0.66).
Discussion
In this large ART roll-out program in South Africa we identified
patients with confirmed virologic failure on second-line ART.
Despite the absence of major PI resistance at first-line ART
failure, most individuals failed second-line ART quickly (e.g.
within a mean of 10 months) and two-thirds failed with wild-type
virus. Furthermore, while patients remained on second-line ART
with continued virologic failure, drug resistance did not develop
over the follow-up period.
Given the known potency of second-line ART regimens and the
low frequency of drug resistant virus found, it appears that
medication non-adherence is an important cause of second-line
ART failure. While access to pharmacy refill, pill count, and
patient-level pharmacokinetic data were not available, there are
plausible patient-level, regimen-specific, and structural explana-
tions for adherence problems on second-line ART. Drug toxicities
related to lopinavir and didanosine and the buffered formulation
of didanosine (the enteric-coated formulation was unavailable at
the study site) likely hindered adherence [18,19]. Social and
structural obstacles to adherence can include inaccessible clinic
location or lack of access to transportation, work/child-care
responsibilities, and decreased health care provider to patient ratio
as a consequence of the rapid growth in ART roll-out programs
Figure 1. Study flow diagram.
doi:10.1371/journal.pone.0032144.g001
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can also be a challenge.
Most patients had substitutions in PR at sites that are known to
be polymorphic in HIV-1 subtype C. These minor resistance
mutations were also present at first-line ART failure in samples
from the 10 patients who had samples available for sequencing
from that time point. This observation confirms a prior genotype
study from this clinic of HIV-infected individuals who were ART-
naı ¨ve and who had failed first-line where the same polymorphisms
in PR were present [4]. It is also consistent with other studies that
performed genotypic analysis of individuals infected with HIV-1
subtype C who were ART-naı ¨ve [23,24,25,26]. The impact of
these polymorphisms has been debated, without clear clinical
evidence that they affect drug susceptibility [27,28].
Despite the absence of NNRTI exposure on second-line ART,
virus from almost 30% of patients had at least one major NNRTI
resistance mutation and virus from 15% had a mutation at the
K103N codon, which suggests ongoing resistance to nevirapine
and efavirenz. The persistence of NNRTI resistance is consistent
with genotypic analysis of two other public sector South African
cohorts of patients that failed PI-based ART [29,30]. The low
frequency of etravirine-associated mutations suggests excellent
susceptibility to this next-generation NNRTI if it were to become
available.
There are several therapeutic implications for the absence of
NRTI resistance at second-line failure in this study. While other
studies have suggested a higher rate of emergence of K65R at the
time of stavudine-based ART failure in HIV-1 subtype C
infection, we found that K65R did not appear after exposure to
first-line stavudine or second-line didanosine; this may hold
promise for the increasing use of tenofovir in resource-limited
settings with predominance of nonsubtype-B HIV clades [31,32].
M184V mutation and TAMs became undetectable supporting the
hypothesis that lack of drug exposure due to ART non-adherence
was the most likely cause of ART failure. In addition,
consideration of archived resistance mutations is important in
selection of second-line ART [33].
Females represented 85% of the patients whose viruses were
sequenced, which is slightly higher than the distribution of
females commencing second-line ART (75%)[9]. While the
demographic and clinical characteristics of the cohort are largely
consistent with other large ART programs, the small sample size
may limit generalizability [34,35]. Limited data were available on
ART adherence, pharmacokinetic data, and contextual co-
variates that may have an important impact on ART use and
effectiveness. For example, those who receive treatment for other
conditions, such as tuberculosis, may experience decreased levels
of lopinavir/ritonavir if they are concomitantly taking rifampicin
[36]. Because data on prior ART exposure, such as for
prevention of mother-to-child transmission were not available,
we limited the analysis to individuals who were documented as
ART naı ¨ve at initiation of first-line ART in the clinical record.
This study did not test for minority drug-resistance variants that
are not detected by conventional genotypic testing but contribute
to ART failure [37].
The low frequency of drug resistance to boosted-lopinavir at the
time of virologic failure in this large ART-roll out program in
Cape Town confirms other studies in Johannesburg and Soweto,
South Africa, as well as in North America and Europe
[29,30,38,39]. In vivo resistance data suggest that the accumulation
of accessory mutations in PR occurs rapidly only after major
protease resistance mutations are established [40]. The absence of
new PR mutations over a short interval of virologic failure on PI-
based second-line ART is consistent with this observation.
In those who experience virologic failure on second-line ART in
South Africa, ART failure occurs quickly and most often with
wild-type virus. However, rapid development of resistance does
not occur. Interventions that successfully improve adherence could
allow patients to continue to benefit from second-line ART
therapy even after initial failure.
Table 1. Distribution of genotypic drug resistance mutations for patients with virologic failure on second-line ART in a large ART
roll-out program in South Africa.
Item No. of patients (Total n=33) % of total 95% CI Low 95% CI High
I. No major mutations 22 67 51 83
II. NNRTI resistance mutations only{ 92 7 1 2 4 3
One mutation
K103N 4 12 1 23
P225H 1 3 0 9
G190A1 13 0 9
Y181C1 13 0 9
Two mutations
K103N, Y181C 1 3 0 9
V106M, V179D1 13 0 9
III. NRTI and NNRTI resistance mutations 2 6 0 14
L74V, M184V (NRTI)
G190A (NNRTI)
13 0 9
T69D, D67DG* (NRTI)
Y181C, G190A (NNRTI)
13 0 9
ART: antiretroviral treatment. PI: protease inhibitor. NRTI: nucleoside reverse transcriptase inhibitor. NNRTI: non-nucleoside reverse transcriptase inhibitor.
*Thymidine analog mutation.
{Mutations at codons L100I, V108I, Y188C, were not detected.
1Mutations reducing etravirine susceptibility. Others found in the cohort include V90I, K101E/P, V106I, and V179D. The A98G, L100I, Y181I/V, and M230L mutations were
not detected.
doi:10.1371/journal.pone.0032144.t001
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